Search | Clinical Trials Finder

Conditions: Nephrotic Syndrome
Interventions: ACTH; Drug
Lead sponsor: Emory University; Other
Eligibility: 2 Years to 20 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 16
States / cities: Birmingham, Alabama • Los Angeles, California • Wilmington, Delaware + 13 more

Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Interventions: Mirikizumab; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 2 Years to 19 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 11
States / cities: San Francisco, California • Hartford, Connecticut • Atlanta, Georgia + 7 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: Indacaterol 75 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis; Industry
Eligibility: 40 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 62
States / cities: Peoria, Arizona • Pine Bluff, Arkansas • Buena Park, California + 57 more

Conditions: Chronic Kidney Disease
Interventions: Diet counseling, Phosphorus binder; Other · Drug
Lead sponsor: Salem Veterans Affairs Medical Center; Federal
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Salem, Virginia

Conditions: CNS Germ Cell Tumor
Interventions: Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).; Drug
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: Not listed
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2019
U.S. locations: 5
States / cities: Phoenix, Arizona • Los Angeles, California • New York, New York + 1 more

Conditions: Hypoglycemia
Interventions: Glucagon; Drug
Lead sponsor: Xeris Pharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 1
States / cities: Walnut Creek, California

Conditions: Brain Tumors
Interventions: Nicardipine, Esmolol; Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Failure
Interventions: Stepped pharmacologic care, Ultrafiltration; Drug · Device
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 8
States / cities: Phoenix, Arizona • Atlanta, Georgia • Minneapolis, Minnesota + 5 more

Conditions: Proteinuria, Transplant Glomerulopathy
Interventions: Acthar; Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Lymphoma, Non-Hodgkin
Interventions: Granulocyte colony-stimulating factor plus plerixafor, Granulocyte colony-stimulating factor plus placebo; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 78 Years
Enrollment: 298 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 31
States / cities: Phoenix, Arizona • Duarte, California • Denver, Colorado + 23 more

Conditions: Persistent Asthma
Interventions: Beclomethasone dipropionate breath-actuated inhaler, Placebo breath-actuated inhaler, albuterol/salbutamol; Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 47
States / cities: Huntington Beach, California • Mission Viejo, California • Orange, California + 41 more

Conditions: Asthma
Interventions: Antipyrine-benzocaine otic solution, Glycerin with Oxyquinoline Sulfate; Drug · Other
Lead sponsor: Global United Pharmaceutical Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Augusta, Georgia

Conditions: Asthma
Interventions: Beclomethasone dipropionate, Albuterol sulfate; Drug
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 6 Years to 18 Years
Enrollment: 288 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2011
U.S. locations: 6
States / cities: Tucson, Arizona • Los Angeles, California • San Diego, California + 3 more

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: indacaterol and glycopyrronium (QVA149), glycopyrronium (NVA237), indacaterol (QAB149), tiotropium, placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 2,144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 14
States / cities: Fullerton, California • Riverside, California • St. Petersburg, Florida + 11 more

Conditions: Patent Ductus Arteriosus, Surgery, Necrotizing Enterocolitis, Intestinal Perforation
Interventions: pharmacologic treatment of the PDA, no pharmacologic treatment of the PDA, NSAID; Other · Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 5 Days to 14 Days
Enrollment: 202 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 13
States / cities: San Diego, California • San Francisco, California • San Jose, California + 9 more

Conditions: Ulcerative Colitis
Interventions: Brazikumab Maintenance Dose, Brazikumab Induction Dose; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 10
States / cities: Chula Vista, California • Lancaster, California • Colorado Springs, Colorado + 7 more

Conditions: Breast Cancer
Interventions: filgrastim, amifostine trihydrate, cyclophosphamide, doxorubicin hydrochloride, paclitaxel, peripheral blood stem cell transplantation; Biological · Drug · Procedure
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 59 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2023
U.S. locations: 1
States / cities: Duarte, California

Conditions: Suicide, Surveillance, Mental Health, Substance Use, Depressive Symptoms
Interventions: New Hope (NH), Elders Resilience (ER), Case Management (CM); Behavioral · Other
Lead sponsor: Johns Hopkins Bloomberg School of Public Health; Other
Eligibility: 16 Years to 29 Years
Enrollment: 304 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Whiteriver, Arizona

Conditions: Asthma
Interventions: Salbutamol HFA-134a, Salbutamol HFA-152a; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 37
States / cities: North Hollywood, California • San Mateo, California • Aventura, Florida + 32 more

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions: Sacituzumab tirumotecan, Bevacizumab, H1 receptor antagonist, H2 receptor antagonist, Acetaminophen (or equivalent), Dexamethasone (or equivalent), Steroid mouthwash (dexamethasone or equivalent); Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 770 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 36
States / cities: Birmingham, Alabama • Anchorage, Alaska • San Francisco, California + 32 more

Conditions: Allergic Rhinitis Due to Dermatophagoides Farinae, Allergic Rhinitis Due to Dermatophagoides Pteronyssinus, Allergic Rhinitis Due to House Dust Mite
Interventions: Sublingual allergy immunotherapy tablet, Placebo; Biological · Other
Lead sponsor: ALK-Abelló A/S; Industry
Eligibility: 5 Years to 11 Years
Enrollment: 1,460 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 29
States / cities: Huntington Beach, California • Los Angeles, California • San Diego, California + 25 more

Conditions: Drowning
Interventions: self-rescue training; Behavioral
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Months to 23 Months
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Obstructive Sleep Apnea
Interventions: Placebo, Acetazolamide, Trazodone, Atomoxetine and eszopiclone; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 21 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hepatitis C
Interventions: DCV/ASV/BMS-791325, Ribavirin, Sofosbuvir, Peginterferon α-2a; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: Not listed
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Rialto, California • Chicago, Illinois • Indianapolis, Indiana + 2 more

Search by objective public record fields.

Adrenocorticotropic Hormone (ACTH) for Frequently Relapsing and Steroid Dependent Nephrotic Syndrome

A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)

12-week Efficacy of Indacaterol

Study Comparing Effects of Lanthanum Carbonate Versus Calcium Acetate Versus Dietary Phosphorus Restriction

Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)

G-Pen™ for Hypoglycemia Rescue in T1D Patients

Nicardipine vs Esmolol Craniotomy Emergence

Effectiveness of Ultrafiltration in Treating People With Acute Decompensated Heart Failure and Cardiorenal Syndrome (The CARRESS Study)

Acthar as Rescue Therapy for Transplant Glomerulopathy in Kidney Transplant Recipients

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma Patients

A 12-week Safety and Efficacy Study of Beclomethasone Dipropionate (80 and 160 mcg/Day) Delivered Via Breath-Actuated Inhaler (BAI) in Patients >=12 Years Old With Persistent Asthma

Assessing the Efficacy of CREWS01 to Decrease Usage of Rescue Inhalers in Moderate to Severe Asthmatic Adults

(CARE Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

A Study to Assess the Efficacy, Safety and Tolerability of Once-daily (q.d.) QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus

Open-label Extension Study of Brazikumab in Ulcerative Colitis

Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer

Southwest Hub for American Indian Youth Suicide Prevention Research

A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

House Dust Mite Allergy Trial In Children

Teaching Young Children Swim Survival Skills

Rescue Pharmacotherapy for OSA

Short Duration Combination Therapy With Daclatasvir, Asunaprevir, BMS-791325 and Sofosbuvir in Subjects Infected With Chronic Hepatitis-C (FOURward Study)